Navigation Links
Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management

HORSHAM, Pa., Dec. 7 /PRNewswire-FirstCall/ -- Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma. This represents the first time leading researchers from various institutions in the U.S. and Canada have organized information surrounding the small airways in asthma to set a benchmark for additional discussion and future research in this area.

Although increasing evidence supports the importance of small airways in the diagnosis and treatment of asthma, focused areas of discussion and critical review of this topic have been lacking. Additionally, while there has been significant progress in the diagnosis of asthma, including prevention, education and treatment, asthma remains a major public health concern as millions of people still experience flare ups and miss school and work days as a result every year.

"It is important for both patients and physicians to have a clear understanding of the role of the small airways in the pathology of asthma," said study author Richard J. Martin, MD, Chairman, Department of Medicine, National Jewish Health in Denver, CO. "Poorly controlled inflammation in the small airways may exacerbate asthma symptoms, such as coughing and shortness of breath, which may lead to an asthma attack or need to seek emergency care. Physicians should consider an inhaled corticosteroid controller medication with a small particle size that delivers medication to both the large and small airways."

The below chart highlights the four articles included in the supplement that were developed following the April 2009 symposium at which leading asthma specialists discussed various aspects surrounding the importance of small airways in asthma management*:

Article Title                                 Key Highlights
-------------                                 --------------
* The Importance and Features                * The small airways play an
  of the Distal Airways in Children            important role in the
  and Adults                                   pathology of asthma
  (E. W. Gelfand and M. Kraft)
                                             * Inflammation of small
                                               airways may exacerbate
                                               asthma, contribute to an
                                               accelerated decline in lung
                                               function and promote airway

* Anatomy, Pathology, and Physiology         * Airway inflammation and
  of the Tracheobronchial Tree: Emphasis       remodeling that
  on the Distal Airways                        characterize asthma occur
  (D. M. Hyde, Q. Hamid and C. G. Irvin)       in the small airways

                                             * Small airways are an
                                               important target for asthma

* Particle Size of Inhaled Corticosteroids:  * HFA solution metered-dose
  Does it Matter?                              inhalers, such as QVAR(R),
  (C. Leach, G. L. Colice and A. Luskin)       produce small particles
                                               that are able to reach and
                                               treat the large and small

                                             * Most inhaled medications do
                                               not reach the small airways
                                               where many of the
                                               pathological changes in
                                               asthma may occur

                                             * Reformulated QVAR(R) does
                                               not have greater systemic

* Imaging of the Distal Airways              * High-resolution CT imaging
  (D. Tashkin and E. E. de Lange)              can assess small airway
                                               role in asthma

                                             * Traditional imaging methods
                                               cannot measure small airway

National guidelines recommend inhaled corticosteroids (ICSs) as first-line therapy to achieve asthma control; however, most of these medications do not reach and treat the small airways due to their large particle size, therefore, small airway inflammation remains largely uncontrolled. There are treatments available with extra-fine particle size, such as QVAR®, which allows asthma control to be delivered deep in the lung, due to more effective penetration throughout the large and small airways. Patients should talk to their healthcare provider to learn more about available treatment options that reach and treat both large and small airways.

* The symposium was funded through an unrestricted grant by Teva Respiratory, LLC.

About Asthma

Asthma is a chronic (long-term), treatable lung disease that causes narrowing of the large and small airways, making breathing difficult at times. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath and coughing that often occurs at night or early in the morning. Without appropriate treatment, asthma symptoms may become more severe and result in an asthma attack, which can lead to hospitalization and even death.

Asthma affects people of all ages, but it most often starts in childhood. In the U.S., more than 22 million people are known to have asthma, including more than 6 million children. Each year in the U.S., asthma causes approximately 500,000 hospitalizations, 134 million days of restricted activity and 4,000 deaths.

About QVAR®

QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information

QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm. Common side effects associated with the use of QVAR® and placebo in clinical trials includes, but is not limited to, headache (12% and 9%, respectively) and pharyngitis (8% and 4%, respectively). Caution: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information). A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment.

For full Prescribing Information please click here:

About Teva Respiratory

Teva Respiratory is the U.S.-based respiratory division of Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Europe.

SOURCE Teva Respiratory, a division of Teva Pharmaceutical Industries, Ltd.

SOURCE Teva Respiratory, a division of Teva Pharmaceutical Industries, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Case Western Reserve researchers new pathway discovery published as Paper of the Week
2. First ever large-scale study of ketamine users published
3. Newly revised guidelines for managing thyroid cancer published in Thyroid journal
4. Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
5. Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research
6. Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
7. Special Autism Issue Published by the College of Optometrists in Vision Development
8. Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control
9. Published Study Shows More Patients See Improvement in Overactive Bladder Symptoms With Urgent(R) PC Device Compared to Those Using a Drug
10. Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation
11. ANAVEX reports sigma receptor review published in leading journal
Post Your Comments:
(Date:11/25/2015)... Ill. (PRWEB) , ... November 25, 2015 , ... ... and potentially more aggressive than those found on mammography, according to a study ... findings of additional cancers not seen on mammography may necessitate a change in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... factory direct sauna parts and accessories. , Sauna accessories help improve the bather ... style and personality. From basic styles for the purist looking for simplicity in ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical show, ... 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this final ... has been a treasured tradition for numerous families in the Evanston community. Over ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
(Date:11/25/2015)... --> --> ... was valued at $11,171.1 million in 2014, and it ... during 2015 - 2022. The global market is growing, ... diabetes. In addition, the increase in obese population and ... the growth of the market. Furthermore, technological advancements in ...
Breaking Medicine Technology: